Network Meta‐Analysis: Efficacy of Biological Therapies and Small Molecules as Maintenance Therapy in Ulcerative Colitis
Alimentary Pharmacology & Therapeutics · 2025-07 · 62 (1) · 4-21
DOI: 10.1111/apt.70209 ↗At a glance
Netzwerk-Metaanalyse in Alimentary Pharmacology & Therapeutics, published online on 2025-05-23. Written by Brigida Barberio and 3 co-authors. Institution: Department of Surgery, Oncology and Gastroenterology (DISCOG), Gastroenterology Unit, University of Padova-Azienda Ospedaliera di Padova, Padova, Ita…. Major MEDLINE topics: Biological Products, Biological Therapy, Colitis, Ulcerative. Cited 15 times so far (Crossref); 61 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background
Numerous biologics and small molecules are licensed as maintenance therapy for ulcerative colitis (UC). Differences in the design of randomised controlled trials (RCTs) have not been considered when comparing efficacy between them.
Aims
To examine the relative efficacy of biologics and small molecules by network meta‐analysis according to trial design.
Methods
We searched the literature to 27 February 2025 for RCTs. We judged efficacy using clinical remission, endoscopic improvement, endoscopic remission, or corticosteroid‐free remission and according to previous exposure or non‐exposure to advanced therapies. Random effects model with data reported as pooled relative risks (RR) with 95% confidence intervals (CI); drugs ranked by p ‐score.
Results
We identified 28 RCTs, 16 re‐randomising 6568 patients and 12 treating through 3771 patients. In re‐randomised studies, upadacitinib 30 mg o.d. ranked first for clinical remission (RR of failure to achieve clinical remission = 0.52; 95% CI 0.44–0.61, p ‐score 0.99) and endoscopic improvement (RR = 0.43; 95% CI 0.35–0.52, p ‐score 0.99). Vedolizumab 300 mg 4‐weekly ranked first for endoscopic remission (RR = 0.73; 95% CI 0.64–0.84, p ‐score 0.92) and guselkumab 200 mg 4‐weekly first for corticosteroid‐free remission (RR = 0.40; 95% CI 0.28–0.55, p ‐score 0.95). In treat‐through studies, etrasimod 2 mg o.d. ranked first for clinical remission (RR = 0.73; 95% CI 0.64–0.83, p ‐score 0.88) and infliximab 10 mg/kg 8‐weekly first for endoscopic improvement (RR = 0.64; 95% CI 0.56–0.74, p ‐score 0.94).
Conclusion
In network meta‐analysis, upadacitinib and etrasimod were consistently efficacious as maintenance therapy in UC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Surgery, Oncology and Gastroenterology (DISCOG), Gastroenterology Unit, University of Padova-Azienda Ospedaliera di Padova, Padova, Italy.
- Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
- Leeds Institute of Medical Research, St. James's, University of Leeds, Leeds, UK.
ORCID profiles: Brigida Barberio, Christopher J Black, Alexander C Ford
Cite
APA
Barberio, B., Gracie, D. J., Black, C. J., & Ford, A. C. (2025). Network Meta‐Analysis: Efficacy of Biological Therapies and Small Molecules as Maintenance Therapy in Ulcerative Colitis. Alimentary Pharmacology & Therapeutics, 62(1), 4-21. https://doi.org/10.1111/apt.70209
Vancouver
Barberio B, Gracie DJ, Black CJ, Ford AC. Network Meta‐Analysis: Efficacy of Biological Therapies and Small Molecules as Maintenance Therapy in Ulcerative Colitis. Alimentary Pharmacology & Therapeutics. 2025;62(1):4-21. doi:10.1111/apt.70209
BibTeX
@article{Barberio2025,
author = {Barberio, Brigida and Gracie, David J and Black, Christopher J and Ford, Alexander C},
title = {Network Meta‐Analysis: Efficacy of Biological Therapies and Small Molecules as Maintenance Therapy in Ulcerative Colitis},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
volume = {62},
number = {1},
pages = {4--21},
doi = {10.1111/apt.70209}
}
EUVIMED